The National Medical Products Administration conditionally approved the marketing of Zenedatumumab for injection

2025-05-29 16:38:53

The National Medical Products Administration has conditionally approved the marketing of Zenidatuzumab for injection (trade name: Bhean) submitted by BeiGene (Suzhou) Biotechnology Co., Ltd. through the priority review and approval procedure. It is suitable for patients with unresectable locally advanced or metastatic biliary tract cancer with high HER2 expression (IHC3+) who have previously received systemic treatment. The launch of this product provides a new treatment option for related patients.

BeiGene

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Hong Kong stocks opened: Hang Seng Index opened 0.14% higher, Hang Seng Technology Index opened 0.13% higher
                            2025-06-06

                                    A U.S. appeals court rejected Apple's (AAPL.O) request to suspend an order on App Store reforms in its lawsuit against Epic Games, court documents showed.
                            2025-06-05

                                    Cainiao continues to deploy logistics + AI and joins hands with China Eastern Airlines to build the world's first smart hangar
                            2025-06-06

                                    South Korea's exports fell 1.3% in May from a year earlier
                            2025-06-01

                                    Project establishment and formulation of safety requirements for combined driving assistance systems for intelligent connected vehicles
                            2025-06-04